Prometic Life Sciences Inc. (QX) Company Description
ProMetic Life Sciences Inc. (www.prometic.com) is an established biopharmaceutical company with widely recognized expertise in bioseparations, plasmaderived therapeutics and small-molecule drug development. ProMetic offers its innovative technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop and commercialize plasma-derived therapeutics. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the United Kingdom, the U.S. and Canada, manufacturing facilities in the United Kingdom and Canada and business development activities in the U.S., Europe and Asia. ProMetic's Common Shares trade on the Toronto Stock Exchange under the symbol "PLI" and the OTCQX International under the symbol "PFSCF".